Biologic Therapies in COPD: Data-Driven Strategies for Clinical Decision-Making
Webinar/Online
Tuesday, February 17, 2026 at 7:00pm ET - 8:15pm ET
Info
Topic
Chronic obstructive pulmonary disease (COPD) care is entering a transformative era. With persistent symptoms and exacerbations on triple therapy, biologics are reshaping treatment pathways. Dupilumab and mepolizumab are the first approved biologics for COPD, with additional agents targeting cytokines thymic stromal lymphopoietin (TSLP), interleukin (IL)-33/ST2, and mucus hypersecretion on the horizon. However, significant gaps remain in clinician confidence with biomarkers, trial interpretation, and treatment selection. As multiple late-stage trials report in 2025–2026, education is critical to equip clinicians with the knowledge and frameworks to integrate biologics into personalized COPD management.
Credits Offered
This event offers
1.25 contact hours
to attendees.
Accreditation Info:
AANP.
Additional Information
TARGET AUDIENCE
This activity addresses the needs of physicians, physician assistants, and nurse practitioners involved in the management of patients with COPD.
LEARNING OBJECTIVES
Upon completion of this educational activity, participants should be able to:
- Identify patients with COPD who are candidates for biologic therapy
- Select appropriate biologic therapies for patients with COPD
- Discuss future pathophysiologic treatment targets including mucus hypersecretion and epithelial alarmins and their potential impact in COPD management
Speakers
Pulmonary Function and Exercise Physiology Lab
University of Alabama–Birmingham
Birmingham, Alabama
Henry Sewall Endowed Professor
Chief, Pulmonary and Critical Care Medicine
University of Michigan
Ann Arbor, Michigan